AG 019

Drug Profile

AG 019

Alternative Names: AG019

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ActoBio Therapeutics
  • Class Antihyperglycaemics; Bacteria; Immunotherapies; Interleukins; Peptides
  • Mechanism of Action Immunomodulators; Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 29 Mar 2018 The US FDA approves IND application for AG 019 in Type-1 diabetes mellitus
  • 29 Mar 2018 Pharmacodynamics data from a preclinical trial in Type-1 diabetes mellitus released by ActoBio Therapeutics
  • 29 Mar 2018 Intrexon T1D Partners plans a phase Ib/IIa trial for Type-1 diabetes mellitus in Europe and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top